Gujarat Themis Biosyn has signed definitive agreement for the acquisition of 100% equity shareholding of MicroBiopharm Japan Co., from funds managed or advised by T Capital Partners Co., a Japan based Private Equity Fund. The acquisition will be executed through a wholly owned special purpose vehicle (SPV) to be incorporated in Japan. The transaction is expected to close during Q2FY27, subject to customary approvals and closing formalities.
This acquisition represents a significant milestone in GTBL’s long-term strategy to evolve from a fermentation-led intermediates business into a technology-driven Contract Development Manufacturing Organization (CDMO) platform with capabilities across precision fermentation, biotechnology, and next-generation drug manufacturing. The consideration for the transaction would be approximately JPY 21.5 billion (approximately Rs 1,300 crores), payable at closing, and is expected to be funded through an optimal mix of debt and equity.
Gujarat Themis Biosyn is a biotech and synthetic product manufacturing company.
